Precisis’ EASEE Epilepsy Treatment Receives FDA Breakthrough Device Designation

March 1, 2022

Heidelberg, Germany-based Precisis has received a Breakthrough Device designation from the FDA for its EASEE brain stimulator.

EASEE is an acronym for epicranial application of stimulation electrodes for epilepsy.

The device uses electrodes that are invisibly positioned underneath the scalp directly on the skull bone to treat epilepsy seizures. The electrodes deliver calming current to the brain in a precisely targeted treatment that takes into account the specific disease history of each patient, the company said.

View today's stories